Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies. Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen / Angela, Rago; Lichtner, Miriam; Sergio, Mecarocci; Raffaella, Marocco; Natalia, Cenfra; Belvisi, Valeria; Cosmo Del Borgo, ; Cimino, Giuseppe; Mastroianni, Claudio Maria. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 15:6(2010), pp. 929-932. [10.3851/imp1633]
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen
LICHTNER, Miriam;Raffaella Marocco;Valeria Belvisi;CIMINO, Giuseppe;MASTROIANNI, Claudio Maria
2010
Abstract
Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies. Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
